Symbols / ATNM $1.04 +0.97% Actinium Pharmaceuticals, Inc.

Healthcare • Biotechnology • United States • ASE
ATNM Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Sandesh C. Seth M.B.A., M.S.
Exch · Country ASE · United States
Market Cap 32.63M
Enterprise Value -8.30M
Income -23.47M
Sales 90.00K
FCF (ttm) -14.79M
Book/sh 0.07
Cash/sh 1.34
Employees 25
Insider 10d —
IPO Dec 27, 2012
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -2.97
PEG —
P/S 362.56
P/B 14.25
P/C —
EV/EBITDA 0.33
EV/Sales -92.19
Quick Ratio 5.73
Current Ratio 5.89
Debt/Eq 65.93
LT Debt/Eq —
EPS (ttm) -0.76
EPS next Y -0.35
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-08
Earnings (prior) 2026-05-08
ROA -27.95%
ROE -167.66%
ROIC —
Gross Margin 100.00%
Oper. Margin -283.47%
Profit Margin 0.00%
Shs Outstand 31.37M
Shs Float 31.04M
Insider Own 2.35%
Instit Own 20.61%
Short Float 3.47%
Short Ratio 9.99
Short Interest 1.08M
52W High 1.89
vs 52W High -44.97%
52W Low 0.95
vs 52W Low 9.24%
Beta -0.05
Impl. Vol. 2.05%
Rel Volume 0.29
Avg Volume 185.90K
Volume 54.64K
Target (mean) $5.00
Tgt Median $4.50
Tgt Low $2.00
Tgt High $9.00
# Analysts 4
Recom Buy
Prev Close $1.03
Price $1.04
Change 0.97%
About

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia. Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$5.00
Mean price target
2. Current target
$1.04
Latest analyst target
3. DCF / Fair value
$-8.49
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.04
Low
$2.00
High
$9.00
Mean
$5.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-31 reit Stephens & Co. Overweight → Overweight $5
2025-06-24 reit HC Wainwright & Co. Buy → Buy $4
2025-05-12 reit HC Wainwright & Co. Buy → Buy $4
2025-04-28 reit HC Wainwright & Co. Buy → Buy $4
2025-04-01 reit HC Wainwright & Co. Buy → Buy $4
2025-03-27 reit HC Wainwright & Co. Buy → Buy $4
2025-03-25 reit HC Wainwright & Co. Buy → Buy $4
2025-03-20 reit HC Wainwright & Co. Buy → Buy $4
2025-03-18 reit HC Wainwright & Co. Buy → Buy $4
2025-03-11 reit HC Wainwright & Co. Buy → Buy $4
2024-11-19 reit Stephens & Co. Overweight → Overweight $5
2024-11-15 reit HC Wainwright & Co. Buy → Buy $4
2024-08-06 main HC Wainwright & Co. Buy → Buy $4
2024-08-06 main Maxim Group Buy → Buy $5
2024-07-26 reit HC Wainwright & Co. Buy → Buy $50
2024-06-17 reit HC Wainwright & Co. Buy → Buy $50
2024-05-21 reit HC Wainwright & Co. Buy → Buy $50
2024-05-14 init Stephens & Co. — → Overweight $25
2024-05-02 reit HC Wainwright & Co. Buy → Buy $50
2024-04-30 reit Cantor Fitzgerald Overweight → Overweight $21
News
RSS: Latest ATNM news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.09
0.00
-100.00%
0.08
-92.14%
1.03
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
36.34
-13.73%
42.12
-19.00%
52.00
+48.01%
35.13
Research And Development
21.12
-29.69%
30.05
-22.30%
38.67
+67.15%
23.14
Selling General And Administration
15.21
+25.98%
12.08
-9.41%
13.33
+11.10%
12.00
General And Administrative Expense
15.21
+25.98%
12.08
-9.41%
13.33
+11.10%
12.00
Other Gand A
15.21
+25.98%
12.08
-9.41%
13.33
+11.10%
12.00
Total Expenses
36.34
-13.73%
42.12
-19.00%
52.00
+48.01%
35.13
Operating Income
-36.25
+13.95%
-42.12
+18.87%
-51.92
-52.24%
-34.10
Total Operating Income As Reported
-36.25
+13.95%
-42.12
+18.87%
-51.92
-52.24%
-34.10
EBITDA
-35.43
+14.24%
-41.31
+19.21%
-51.13
-53.06%
-33.41
Normalized EBITDA
-35.43
+14.24%
-41.31
+19.21%
-51.13
-53.06%
-33.41
Reconciled Depreciation
0.82
+1.23%
0.81
+2.66%
0.79
+13.02%
0.70
EBIT
-36.25
+13.95%
-42.12
+18.87%
-51.92
-52.24%
-34.10
Net Income
-33.89
+11.39%
-38.24
+21.66%
-48.82
-47.86%
-33.02
Pretax Income
-33.89
+11.39%
-38.24
+21.66%
-48.82
-47.86%
-33.02
Net Non Operating Interest Income Expense
2.36
-39.14%
3.88
+25.02%
3.10
+185.37%
1.09
Net Interest Income
2.36
-39.14%
3.88
+25.02%
3.10
+185.37%
1.09
Interest Income Non Operating
2.36
-39.14%
3.88
+25.02%
3.10
+185.37%
1.09
Interest Income
2.36
-39.14%
3.88
+25.02%
3.10
+185.37%
1.09
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-33.89
+11.39%
-38.24
+21.66%
-48.82
-47.86%
-33.02
Net Income From Continuing Operation Net Minority Interest
-33.89
+11.39%
-38.24
+21.66%
-48.82
-47.86%
-33.02
Net Income From Continuing And Discontinued Operation
-33.89
+11.39%
-38.24
+21.66%
-48.82
-47.86%
-33.02
Net Income Continuous Operations
-33.89
+11.39%
-38.24
+21.66%
-48.82
-47.86%
-33.02
Normalized Income
-33.89
+11.39%
-38.24
+21.66%
-48.82
-47.86%
-33.02
Net Income Common Stockholders
-33.89
+11.39%
-38.24
+21.66%
-48.82
-47.86%
-33.02
Otherunder Preferred Stock Dividend
—
—
—
—
Diluted EPS
-1.09
+14.17%
-1.27
+30.60%
-1.83
-33.58%
-1.37
Basic EPS
-1.09
+14.17%
-1.27
+30.60%
-1.83
-33.58%
-1.37
Basic Average Shares
31.20
+3.74%
30.07
+13.03%
26.60
+10.20%
24.14
Diluted Average Shares
31.20
+3.74%
30.07
+13.03%
26.60
+10.20%
24.14
Diluted NI Availto Com Stockholders
-33.89
+11.39%
-38.24
+21.66%
-48.82
-47.86%
-33.02
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
51.77
-32.67%
76.90
-5.58%
81.44
-28.68%
114.19
Current Assets
49.38
-33.72%
74.51
-4.80%
78.26
-29.46%
110.94
Cash Cash Equivalents And Short Term Investments
48.00
-34.16%
72.90
-4.92%
76.68
-29.60%
108.91
Cash And Cash Equivalents
48.00
-34.16%
72.90
-4.92%
76.68
-29.60%
108.91
Prepaid Assets
1.22
-2.41%
1.25
-8.46%
1.36
-13.43%
1.57
Restricted Cash
—
—
0.00
-100.00%
0.40
Other Current Assets
0.17
-52.94%
0.36
+57.96%
0.23
+247.69%
0.07
Total Non Current Assets
2.39
+0.04%
2.39
-24.80%
3.18
-2.09%
3.25
Net PPE
2.06
-0.48%
2.07
-27.88%
2.87
-2.68%
2.95
Gross PPE
3.12
+5.51%
2.96
-16.92%
3.56
+3.73%
3.44
Accumulated Depreciation
-1.06
-19.42%
-0.89
-28.39%
-0.69
-42.51%
-0.49
Machinery Furniture Equipment
0.44
+0.00%
0.44
+0.00%
0.44
+39.05%
0.32
Construction In Progress
0.10
0.00
—
—
Other Properties
2.58
+2.34%
2.52
-19.30%
3.12
+0.16%
3.12
Non Current Prepaid Assets
—
—
—
—
Other Non Current Assets
0.34
+3.40%
0.32
+3.51%
0.31
+3.64%
0.30
Total Liabilities Net Minority Interest
43.94
-0.45%
44.14
-2.05%
45.07
-5.54%
47.71
Current Liabilities
7.97
-2.20%
8.15
-4.07%
8.49
-20.08%
10.63
Payables And Accrued Expenses
7.25
-4.24%
7.57
-4.84%
7.95
-21.49%
10.13
Current Debt And Capital Lease Obligation
0.72
+24.48%
0.58
+7.21%
0.54
+8.63%
0.50
Current Capital Lease Obligation
0.72
+24.48%
0.58
+7.21%
0.54
+8.63%
0.50
Current Deferred Liabilities
—
—
—
0.00
Current Deferred Revenue
—
—
—
0.00
Other Current Liabilities
—
—
—
—
Total Non Current Liabilities Net Minority Interest
35.97
-0.06%
35.99
-1.58%
36.57
-1.38%
37.08
Long Term Debt And Capital Lease Obligation
0.97
-2.11%
0.99
-36.83%
1.57
-24.53%
2.08
Long Term Capital Lease Obligation
0.97
-2.11%
0.99
-36.83%
1.57
-24.53%
2.08
Non Current Deferred Liabilities
35.00
+0.00%
35.00
+0.00%
35.00
+0.00%
35.00
Non Current Deferred Revenue
35.00
+0.00%
35.00
+0.00%
35.00
+0.00%
35.00
Stockholders Equity
7.83
-76.09%
32.76
-9.95%
36.38
-45.28%
66.48
Common Stock Equity
7.83
-76.09%
32.76
-9.95%
36.38
-45.28%
66.48
Capital Stock
0.03
+0.00%
0.03
+10.71%
0.03
+7.69%
0.03
Common Stock
0.03
+0.00%
0.03
+10.71%
0.03
+7.69%
0.03
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
31.20
+0.00%
31.20
+12.89%
27.63
+7.63%
25.67
Ordinary Shares Number
31.20
+0.00%
31.20
+12.89%
27.63
+7.63%
25.67
Additional Paid In Capital
417.54
+2.20%
408.55
+9.26%
373.93
+5.27%
355.22
Retained Earnings
-409.71
-9.02%
-375.83
-11.33%
-337.58
-16.91%
-288.76
Gains Losses Not Affecting Retained Earnings
-0.02
0.00
—
—
Other Equity Adjustments
-0.02
—
—
—
Total Equity Gross Minority Interest
7.83
-76.09%
32.76
-9.95%
36.38
-45.28%
66.48
Total Capitalization
7.83
-76.09%
32.76
-9.95%
36.38
-45.28%
66.48
Working Capital
41.41
-37.59%
66.36
-4.89%
69.77
-30.45%
100.31
Invested Capital
7.83
-76.09%
32.76
-9.95%
36.38
-45.28%
66.48
Total Debt
1.69
+7.69%
1.57
-25.56%
2.11
-18.13%
2.58
Capital Lease Obligations
1.69
+7.69%
1.57
-25.56%
2.11
-18.13%
2.58
Net Tangible Assets
7.83
-76.09%
32.76
-9.95%
36.38
-45.28%
66.48
Tangible Book Value
7.83
-76.09%
32.76
-9.95%
36.38
-45.28%
66.48
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-24.58
+25.68%
-33.07
+30.13%
-47.34
-647.61%
8.64
Cash Flow From Continuing Operating Activities
-24.58
+25.68%
-33.07
+30.13%
-47.34
-647.61%
8.64
Net Income From Continuing Operations
-33.89
+11.39%
-38.24
+21.66%
-48.82
-47.86%
-33.02
Depreciation Amortization Depletion
0.82
+1.23%
0.81
+2.66%
0.79
+13.02%
0.70
Depreciation
0.82
+1.23%
0.81
+2.66%
0.79
—
Depreciation And Amortization
0.82
+1.23%
0.81
+2.66%
0.79
+13.02%
0.70
Stock Based Compensation
9.19
+73.66%
5.29
+37.74%
3.84
+37.46%
2.79
Change In Working Capital
-0.70
+24.46%
-0.93
+70.40%
-3.15
-108.25%
38.17
Change In Prepaid Assets
0.22
+1560.00%
-0.01
-130.61%
0.05
+131.01%
-0.16
Change In Payables And Accrued Expense
-0.35
+10.59%
-0.39
+82.22%
-2.18
-147.38%
4.59
Change In Other Working Capital
—
—
—
34.00
Change In Other Current Assets
—
0.00
+100.00%
-0.53
0.00
Change In Other Current Liabilities
-0.58
-8.87%
-0.53
-7.29%
-0.49
-81.62%
-0.27
Investing Cash Flow
-0.10
-845.45%
-0.01
+92.81%
-0.15
+58.20%
-0.37
Cash Flow From Continuing Investing Activities
-0.10
-845.45%
-0.01
+92.81%
-0.15
+58.20%
-0.37
Net PPE Purchase And Sale
-0.10
-845.45%
-0.01
+92.81%
-0.15
+58.20%
-0.37
Purchase Of PPE
-0.10
-845.45%
-0.01
+92.81%
-0.15
+58.20%
-0.37
Capital Expenditure
-0.10
-845.45%
-0.01
+92.81%
-0.15
+58.20%
-0.37
Financing Cash Flow
-0.22
-100.74%
29.32
+97.18%
14.87
-35.65%
23.11
Cash Flow From Continuing Financing Activities
-0.22
-100.74%
29.32
+97.18%
14.87
-35.65%
23.11
Net Issuance Payments Of Debt
-0.01
-11.11%
-0.01
-125.00%
-0.00
+91.84%
-0.05
Repayment Of Debt
-0.01
-11.11%
-0.01
-125.00%
-0.00
+91.84%
-0.05
Long Term Debt Payments
-0.01
-11.11%
-0.01
-125.00%
-0.00
+91.84%
-0.05
Net Long Term Debt Issuance
-0.01
-11.11%
-0.01
-125.00%
-0.00
+91.84%
-0.05
Net Common Stock Issuance
0.00
-100.00%
29.25
+100.21%
14.61
-36.90%
23.16
Proceeds From Stock Option Exercised
0.00
-100.00%
0.07
-71.37%
0.26
0.00
Net Other Financing Charges
-0.21
—
—
—
Changes In Cash
-24.90
-561.91%
-3.76
+88.47%
-32.62
-203.92%
31.39
Effect Of Exchange Rate Changes
0.01
0.00
—
—
Beginning Cash Position
73.23
-4.89%
76.99
-29.76%
109.61
+40.13%
78.22
End Cash Position
48.33
-34.00%
73.23
-4.89%
76.99
-29.76%
109.61
Free Cash Flow
-24.68
+25.39%
-33.08
+30.33%
-47.49
-673.67%
8.28
Interest Paid Supplemental Data
—
0.00
0.00
0.00
Income Tax Paid Supplemental Data
—
0.00
0.00
0.00
Common Stock Issuance
0.00
-100.00%
29.25
+100.21%
14.61
-36.90%
23.16
Issuance Of Capital Stock
0.00
-100.00%
29.25
+100.21%
14.61
-36.90%
23.16
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category